Defense across FDA, DEA, and the state board.
FDA enforcement on compounding pharmacies has accelerated under the Drug Quality and Security Act (DQSA). The agency has issued more than 135 Warning Letters to compounders in the last 24 months alone, with particular focus on 503A and 503B compounding of GLP-1 receptor agonists, peptides, and sterile preparations under USP 797.
A single FDA inspection finding can produce a Warning Letter, a consent decree, a state board referral, and parallel DEA controlled substance scrutiny. Health Law Alliance defends 503A pharmacies and 503B outsourcing facilities nationwide. Our bench includes Dr. Martha Rumore, a nationally recognized pharmacist-attorney and registered patent attorney with 200+ publications in FDA, DEA, and pharmacy law. Every day after a Form 483 changes the realistic exposure.
.png)
By the time the FDA investigator hands you the Form 483, the agency has already built the inspection record. Here is what your facility is actually defending against.
A Form 483 that is not adequately addressed in the 15-day response window can escalate to a public Warning Letter within months. Warning Letters routinely escalate to consent decrees, seizure, and injunctive relief proceedings. The FDA Inspectional Observations and the response record are publicly indexed and form the foundation of any private follow-on litigation.
FDA inspection findings on compounding pharmacies are routinely shared with the state board of pharmacy and the DEA. State board action can suspend or revoke the pharmacy license. DEA action on controlled substance compounding can produce an Order to Show Cause against the registration. Defense has to address all three forums simultaneously.
Severe FDA enforcement matters can produce criminal Federal Food, Drug, and Cosmetic Act prosecutions for adulteration and misbranding under the Park doctrine, with corporate-officer strict liability exposure. The criminal referral runs through the local U.S. Attorney or DOJ Consumer Protection Branch. The criminal track and the civil enforcement track are admissible into one another and require coordinated defense from day one.
Four structural features make compounding matters uniquely complex - and uniquely defensible, if you know how DQSA, FDA, the state board, and DEA actually interact.
Our bench includes Dr. Martha Rumore (pharmacist-attorney + registered patent attorney + 200+ publications in FDA, DEA, and pharmacy law) and a former Assistant U.S. Attorney with DOJ Director's Award recognition. This is the protocol.
Within 24 hours: parse every observation in the Form 483, identify the regulatory framework cited (DQSA, USP 797, cGMP, Bulks List), preserve facility records, batch records, and environmental monitoring data, and put a litigation hold in place.
Observation-by-observation reconstruction: facility design and engineering controls, personnel training records, environmental monitoring, batch records, dispense records, and the underlying regulatory framework on the date of the cited conduct. Every observation gets its own response memo.
We draft and file the written 15-business-day Form 483 response, document the corrective actions taken or planned, and address each cited observation with the substantive regulatory framework that governs it. The response shapes whether the matter resolves with the Form 483 or escalates to a Warning Letter.
If FDA escalates to a Warning Letter, consent decree, or criminal referral, we coordinate the FDA defense with parallel DEA and state board defense and any criminal referral that follows. The pharmacist-attorney + federal-prosecutor bench addresses all forums as one matter.
If any of these describe your facility's recent compounding activity, you are already in the inspection pool whether or not FDA has scheduled the visit.
Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.
Recoupment Reversed
A 503A compounding pharmacy received an FDA Form 483 with multiple observations following an unannounced inspection. HLA addressed each observation in a privileged 15-business-day written response with corrective action plans tied to the substantive USP 797 and DQSA framework. FDA closed the matter without escalating to a Warning Letter.
Network Reinstated
A compounding pharmacy was referred to the state board of pharmacy following a complaint regarding compounded semaglutide dispensing during the FDA shortage period. HLA's response to the board reconstructed the dispense-date Bulks List status, the underlying patient-specific prescriptions, and the USP 797 compliance posture. The state board closed the matter with no discipline.
State Board Closed
A 503B outsourcing facility received FDA Inspectional Observations citing cGMP gaps in process validation and environmental monitoring. HLA coordinated the written response, the remediation plan, and the follow-on FDA communication. The matter resolved through documented remediation without escalation to a Warning Letter or consent decree.
Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific audit.
Anthony's background as a former federal prosecutor and executive for major healthcare companies provided a level of expertise and insight that made all the difference. His deep understanding of healthcare law, particularly in litigation and compliance matters, helped navigate complex legal issues with ease.
Eight questions that come up on almost every first call.
Before you draft your Form 483 response, have a privileged conversation with a pharmacist-attorney bench that has handled 503A and 503B matters across the country. We work the substantive findings, from USP 797 environmental data to beyond-use date assignment and batch-record integrity. Free, confidential, no retainer.
